The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind,placebo controlled,crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

Abstract

Background:

Insomnia is common in patients with major depressive disorder. Although antidepressants improve mood, insomnia often persists as a result of physiological hyperarousal. The orexin-2 receptor is increasingly being recognized as a new target for the treatment of persistent insomnia in major depressive disorder .

Aim:

This exploratory study investigated the effects of seltorexant on objective sleep parameters and subjective depressive symptoms in antidepressant treated major depressive disorder patients with persistent insomnia.

Methods:

Twenty male and female patients received a single dose of 10, 20, 40 mg seltorexant and placebo with a washout period of seven days in a double-blind four-way crossover study. Effects on latency to persistent sleep, total sleep time and sleep efficiency were assessed with polysomnography. Subjective changes in mood were explored by the Quick Inventory of Depressive Symptomatology Self-Report. Safety was recorded and suicidal ideation and behavior were assessed with the Columbia Suicide Severity Rating Scale.

Results:

Latency to persistent sleep was significantly shorter for all doses of seltorexant compared to placebo. Placebo least square mean was 61.05 min with least square mean ratios treatment/placebo (80% confidence interval) of 0.32 (0.24–0.44), 0.15 (0.11–0.2) and 0.17 (0.12–0.23) 19.69, 9.2, 10.15 for 10, 20 and 40 mg seltorexant respectively, (all p<0.001). Total sleep time was significantly longer for all doses of seltorexant compared to placebo. Sleep efficiency was significantly improved. The Quick Inventory of Depressive Symptomatology Self-Report demonstrated a trend to mood-improvement for the 40 mg group.

Conclusions:

Seltorexant showed a statistically significant, dose-dependent decrease in latency to persistent sleep, and increase in total sleep time and sleep efficiency combined with a tendency toward subjectively improved mood.

Keywords

Depression insomnia orexin 2 antagonist

Get full access to this article

View all access options for this article.

References

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association.

Baglioni

Battagliese

Feige

et al . (2011) Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 135: 10–19.

Basta

Chrousos

Vela-Bueno

et al . (2007) Chronic insomnia and stress system. Sleep Med Clin 2: 279–291.

Bonaventure

Shelton

Yun

et al . (2015) Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther 354: 471–482.

Bond

Lader

(1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211–218.

Born

Gauvin

Mukherjee

et al . (2017) Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 86: 181–192.

De Boer

Drevets

Rofael

et al . (2018) A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol 32: 668–677.

Fava

(2004) Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 65(Suppl 16): 27–32.

Gotter

Forman

Harrell

et al . (2016) Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. Sci Rep 6: 27147.

10.

Groeneveld

Hay

van Gerven

(2016) Measuring blood–brain barrier penetration using the NeuroCart, a CNS test battery. Drug Discov Today Technol 20: 27–34.

11.

Hoch

van Gorsel

van Gerven

et al . (2014) Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant. J Clin Pharmacol 54: 979–986.

12.

Hoever

de Haas

Winkler

et al . (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: An ascending single-dose study with almorexant. Clin Pharmacol Ther 87: 593–600.

13.

Kisanuki

Chemelli

Sinton

et al . (2000) The role of orexin receptor type-1 (OX1R) in the regulation of sleep. Sleep 23: A91.

14.

Kuriyama

Tabata

(2016) Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev 35: 1–7.

15.

Letavic

Bonaventure

Carruthers

et al . (2015) Novel octahydropyrrolo[3,4-c]pyrroles are selective orexin-2 antagonists: SAR leading to a clinical candidate. J Med Chem 58: 5620–5636.

16.

Mayers

Baldwin

(2005) Antidepressants and their effect on sleep. Hum Psychopharmacol 20: 533–559.

17.

Peyron

Faraco

Rogers

et al . (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6: 991–997.

18.

Pigeon

Hegel

Unutzer

et al . (2008) Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep 31: 481–488.

19.

Rechtschaffen

Kales

(1968) A manual of standardized terminology, techniques, and scoring systems for sleep stages of human subjects. Electroencephalogr Clin Neurophysiol 26: 644.

20.

Rhyne

Anderson

(2015) Suvorexant in insomnia: Efficacy, safety and place in therapy. Ther Adv Drug Saf 6: 189–195.

21.

Riemann

Spiegelhalder

Feige

et al . (2010) The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Med Rev 14: 19–31.

22.

Riemann

Voderholzer

(2003) Primary insomnia: A risk factor to develop depression? J Affect Disord 76: 255–259.

23.

Rijnbeek

de Visser

Franson

et al . (2003) REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 17: 196–203.

24.

Roth

Zorick

Wittig

et al . (1982) Pharmacological and medical considerations in hypnotic use. Sleep 5(Suppl. 1): S46–S52.

25.

Rush

Trivedi

Ibrahim

et al . (2003) The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573–583.

26.

Sakurai

(2007) The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci 8: 171–181.

27.

Sakurai

Amemiya

Ishii

et al . (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573–585.

28.

Schneider

Fulda

Schulz

(2004) Daytime variation in performance and tiredness/sleepiness ratings in patients with insomnia, narcolepsy, sleep apnea and normal controls. J Sleep Res 13: 373–383.

29.

Schoedel

Sun

Sellers

et al . (2016) Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study. J Clin Psychopharmacol 36: 314–323.

30.

Treiber

de Kanter

Roch

et al . (2017) The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468. J Pharmacol Exp Ther 362: 489–503.

31.

Tsuno

Besset

Ritchie

(2005) Sleep and depression. J Clin Psychiatry 66: 1254–1269.

32.

van der Ark

Golor

van Nueten

et al . (2018) Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J Psychopharmacol 32: 1330–1340.

33.

Vreeburg

Hoogendijk

DeRijk

et al . (2013) Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. Psychoneuroendocrinology 38: 1494–1502.

34.

Young

(2004) Cortisol in mood disorders. Stress 7: 205–208.

35.

Yun

Wennerholm

Shelton

et al . (2017) Selective inhibition of orexin-2 receptors prevents stress-induced ACTH release in mice. Front Behav Neurosci 11: 83.